| Literature DB >> 29246518 |
Andrés Julián Gutiérrez-Escobar1, Gina Méndez-Callejas2.
Abstract
Cancer causes millions of deaths annually and microtubule-targeting agents (MTAs) are the most commonly-used anti-cancer drugs. However, the high toxicity of MTAs on normal cells raises great concern. Due to the non-selectivity of MTA targets, we analyzed the interaction network in a non-cancerous human cell. Subnetworks of fourteen MTAs were reconstructed and the merged network was compared against a randomized network to evaluate the functional richness. We found that 71.4% of the MTA interactome nodes are shared, which affects cellular processes such as apoptosis, cell differentiation, cell cycle control, stress response, and regulation of energy metabolism. Additionally, possible secondary targets were identified as client proteins of interphase microtubules. MTAs affect apoptosis signaling pathways by interacting with client proteins of interphase microtubules, suggesting that their primary targets are non-tumor cells. The paclitaxel and doxorubicin networks share essential topological axes, suggesting synergistic effects. This may explain the exacerbated toxicity observed when paclitaxel and doxorubicin are used in combination for cancer treatment.Entities:
Keywords: Apoptosis; Cancer biology; Cancer treatment; Interactome analysis; Microtubule-targeting agent
Mesh:
Substances:
Year: 2017 PMID: 29246518 PMCID: PMC5828656 DOI: 10.1016/j.gpb.2017.04.006
Source DB: PubMed Journal: Genomics Proteomics Bioinformatics ISSN: 1672-0229 Impact factor: 7.691
Figure 1Comparative analysis of the topological properties between the random network and the MTA interactome
A. Node distribution according to the node degree relative to the number of neighbours for random network. B. Node distribution according to the node degree relative to the number of neighbours for MTA interactome. C. Node distribution for betweenness centrality relative to neighbour distribution for random network. D. Node distribution for betweenness centrality relative to neighbour distribution for MTA interactome. E. Node distribution for closeness centrality relative to the number of neighbours for random network. F. Node distribution for closeness centrality relative to the number of neighbours for MTA interactome. MTA, microtubule-targeting agent.
Top 50 essential nodes of the integrated MTA network
| 268 | 0.126 | 0.558 | 612,662 | |
| 212 | 0.020 | 0.487 | 255,818 | |
| 210 | 0.050 | 0.521 | 343,900 | |
| 203 | 0.017 | 0.483 | 233,252 | |
| 198 | 0.032 | 0.489 | 264,296 | |
| 191 | 0.040 | 0.500 | 298,950 | |
| 181 | 0.053 | 0.500 | 261,470 | |
| 180 | 0.012 | 0.474 | 165,748 | |
| 177 | 0.009 | 0.455 | 124,806 | |
| 168 | 0.011 | 0.476 | 174,648 | |
| 165 | 0.010 | 0.468 | 142,518 | |
| Paclitaxel | 165 | 0.141 | 0.488 | 1,184,898 |
| 150 | 0.078 | 0.531 | 603,234 | |
| 139 | 0.075 | 0.522 | 786,472 | |
| 133 | 0.005 | 0.456 | 91,826 | |
| 124 | 0.039 | 0.514 | 450,050 | |
| 121 | 0.004 | 0.434 | 67,272 | |
| 115 | 0.005 | 0.458 | 76,740 | |
| 111 | 0.030 | 0.508 | 529,562 | |
| 106 | 0.007 | 0.444 | 69,732 | |
| 102 | 0.001 | 0.425 | 29,842 | |
| 100 | 0.001 | 0.426 | 28,990 | |
| 100 | 0.031 | 0.498 | 382,750 | |
| 98 | 0.031 | 0.479 | 180,766 | |
| 98 | 9.73E−04 | 0.426 | 23,082 | |
| 90 | 0.006 | 0.449 | 82,236 | |
| 89 | 0.003 | 0.445 | 52,784 | |
| 88 | 7.64E−04 | 0.421 | 21,772 | |
| 88 | 8.44E−04 | 0.422 | 17,428 | |
| 87 | 0.024 | 0.458 | 286,248 | |
| 87 | 0.039 | 0.484 | 406,936 | |
| 87 | 0.015 | 0.487 | 286,352 | |
| 85 | 0.002 | 0.445 | 51,444 | |
| 84 | 0.003 | 0.446 | 61,686 | |
| 81 | 0.020 | 0.468 | 1961,84 | |
| Docetaxel | 80 | 0.055 | 0.485 | 273,726 |
| 79 | 6.95E−04 | 0.421 | 13,264 | |
| 79 | 0.0030 | 0.445 | 49,924 | |
| 78 | 0.0293 | 0.460 | 264,080 | |
| 74 | 0.0012 | 0.421 | 22,752 | |
| 74 | 2.40E−04 | 0.403 | 4178 | |
| 73 | 0.013 | 0.458 | 148,942 | |
| 73 | 0.019 | 0.485 | 334,388 | |
| 73 | 0.009 | 0.441 | 53,276 | |
| 72 | 0.001 | 0.421 | 21,130 | |
| 72 | 0.001 | 0.421 | 21,130 | |
| 72 | 0.003 | 0.441 | 45,090 | |
| 71 | 1.95E−04 | 0.402 | 3788 | |
| 71 | 1.95E−04 | 0.402 | 3788 |
Figure 2Essential nodes for information flow in the integrated MTA network
A fitted line and its slope were calculated to identify the most significant nodes and MTAs that modulate the information flow in the integrated network, using the betweenness centrality and stress values. Betweenness centrality represents the number of times a node is visited and stress indicates how many times a particular node is part of different shortest paths. The most relevant MTAs in the information flow of the network are underlined.
Functional domains and the associated essential nodes of the integrated MTA network
| 1 | Regulation of apoptosis | 1.11E−33 | 2.36E−26 | |
| Regulation of cell proliferation | 1.61E−23 | 1.23E−06 | ||
| Protein polymerization | 1.98E−11 | 1.31E−06 | ||
| Regulation of locomotion | 7.26E−14 | 1.58E−05 | ||
| Negative regulation of leukocyte proliferation | 5.72E−03 | 6.21E−03 | ||
| 2 | Exogenous drug catabolic process | 2.93E−11 | 6.67E−10 | |
Essential nodes grouped according to their KEGG biological function
| Apoptosis | 5200 | Pathways in cancer | 1.8E−39 | |
| 4151 | PI3K–Akt signaling pathway | 5.94E−15 | ||
| 5210 | Colorectal cancer | 2.28E−22 | ||
| 5206 | MicroRNAs in cancer | 1.63E−17 | ||
| 5212 | Pancreatic cancer | 1.01E−19 | ||
| 4068 | FoxO signaling pathway | 2.01E−16 | ||
| 5205 | Proteoglycans in cancer | 9.18E−14 | ||
| 5222 | Small cell lung cancer | 4.22E−16 | ||
| 5215 | Prostate cancer | 4.35E−16 | ||
| Proliferation | 4110 | Cell cycle | 0.000145 | |
| 4115 | p53 signaling pathway | 0.000679 | ||
| 4668 | TNF signaling pathway | 0.00241 | ||
| Locomotion | 5219 | Bladder cancer | 5.44E−05 | |
| 4915 | Estrogen signaling pathway | 0.000331 | ||
| 4670 | Leukocyte transendothelial migration | 0.000406 | ||
| 5205 | Proteoglycans in cancer | 0.00232 | ||
| Metabolism | 140 | Steroid hormone biosynthesis | 4.53E−13 | |
| 5204 | Chemical carcinogenesis | 1.31E−09 | ||
| 980 | Metabolism of xenobiotics by cytochrome P450 | 2.62E−07 | ||
| 53 | Ascorbate and aldarate metabolism | 3.23E−06 | ||
| 40 | Pentose and glucuronate interconversions | 6.37E−06 | ||
| 1100 | Metabolic pathways | 9.02E−06 | ||
| 860 | Porphyrin and chlorophyll metabolism | 9.33E−06 | ||
| 500 | Starch and sucrose metabolism | 1.37E−05 | ||
| Drug catabolism | 982 | Drug metabolism–cytochrome P450 | 7.80E−09 | |
| 591 | Linoleic acid metabolism | 1.38E−05 | ||
| 2010 | ABC transporters | 3.31E−05 | ||
Figure 3MTA, DDA, and MTA–DDA human interactomes
A. Subnetworks of 2-methoxyestradiol, colchicine, combretastatin A4, docetaxel, epothilone, epothilone B, estramustine, nocodazole, noscapine, paclitaxel, podophyllotoxin, spongistatin, tasidotin, vinblastine, vincristine, vindesine, vinorelbine were merged to produce the integrated MTA interactome. B. The doxorubicin compound was used to produce the DDA interactome. C. The paclitaxel and doxorubicin subnetworks were merged to produce the human MTA–DDA interactome Subnetworks were constructed using STICH 4.0 database http://stitch.embl.de/ with the following criteria: a confidence score of 0.500 with 500 interactions; forcing search saturation; and all prediction methods being active. The MTA, DDA and MTA–DDA networks were created using Cytoscape version 3.4.0 [46] and merged using the Merge Networks plugin [http://www.cytoscape.org/plugins2.php]. MTA, microtubule-targeting agent; DDA, DNA-damaging agent.